Phathom Pharmaceuticals, Inc. (PHAT)

Market Cap	275.56M
Revenue (ttm)	55.25M
Net Income (ttm)	-334.33M
Shares Out	68.38M
EPS (ttm)	-5.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	956,154
Open	4.260
Previous Close	4.225
Day's Range	4.075 - 4.260
52-Week Range	3.810 - 19.710
Beta	0.35
Analysts	Strong Buy
Price Target	22.50 (+451.47%)
Earnings Date	May 8, 2025

About PHAT

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for gastrointestinal diseases. The company develops its products based on vonozopran, an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. Its products under development include VOQUEZNA, which has completed its Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and its Phase II clinical trials for the as-needed dosing for active heartburn episodes; and ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 25, 2019
• Employees: 427
• Stock Exchange: NASDAQ
• Ticker Symbol: PHAT
• Website: https://www.phathompharma.com

Financial Performance

In 2024, Phathom Pharmaceuticals's revenue was $55.25 million, an increase of 8001.47% compared to the previous year's $682,000. Losses were -$334.33 million, 65.8% more than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for PHAT stock is "Strong Buy." The 12-month stock price forecast is $22.5, which is an increase of 451.47% from the latest price.

Price Target

$22.5

(451.47% upside)

Analyst Consensus: Strong Buy